Article
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
The New England journal of medicine - 29 Nov 2012
Cortes Jorge E, Kantarjian Hagop, Shah Neil P, Bixby Dale, Mauro Michael J, Flinn Ian, O'Hare Thomas, Hu Simin, Narasimhan Narayana I, Rivera Victor M, Clackson Tim, Turner Christopher D, Haluska Frank G, Druker Brian J, Deininger Michael W N, Talpaz Moshe
Abstract excerpt
BACKGROUND: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.